Hoggar (Doxylamine Hydrogen Succinate)

Hoggar is used to alleviate symptoms associated with several common conditions. It may be selected by individuals seeking temporary relief from:

• Allergic rhinitis and hay fever symptoms such as sneezing, runny nose, and itchy eyes
• Mild to moderate symptoms of the common cold, including nasal congestion and watery eyes
• Occasional insomnia when a short‑acting sedative effect is desired
• Seasonal allergy flare‑ups that interfere with daily activities

• Doxylamine hydrogen succinate acts as a selective antagonist of histamine H1 receptors in the central nervous system and peripheral tissues. By blocking these receptors, it prevents histamine‑mediated responses that cause vasodilation, increased vascular permeability, and sensory nerve stimulation, thereby reducing allergic symptoms and producing a sedative effect that can aid sleep.

Adverse reactions to Hoggar vary in frequency and severity.

Common

• Drowsiness or sedation
• Dry mouth, throat, or nasal passages
• Dizziness or light‑headedness
• Constipation or gastrointestinal discomfort
• Blurred vision
• Headache

Serious

• Severe allergic reactions (rash, itching, swelling, difficulty breathing)
• Cardiac arrhythmias in susceptible individuals
• Marked confusion or hallucinations
• Persistent urinary retention

Before using Hoggar, consider the following safety points:

• Avoid taking the product if you have known hypersensitivity to doxylamine or other antihistamines.
• Use caution when operating machinery or driving, as drowsiness may impair alertness.
• Discuss use with a healthcare professional if you have glaucoma, enlarged prostate, or urinary retention.
• Pregnant or breastfeeding individuals should seek medical advice before use.
• Do not combine with other sedating medications or alcohol without guidance.
• Keep out of reach of children; accidental ingestion can be hazardous.

Hoggar may interact with other substances, affecting its safety or effectiveness.

Avoid

• Alcohol, which can intensify sedation and respiratory depression.
• Other central nervous system depressants (e.g., benzodiazepines, opioids, antihistamines).
• Monoamine oxidase inhibitors (MAOIs) within 14 days of use.

Use with caution

• Anticholinergic drugs (e.g., tricyclic antidepressants, antipsychotics) that may increase dry‑mouth or urinary retention.
• CYP2D6 substrates, as doxylamine can modestly inhibit this enzyme.
• Over‑the‑counter cough and cold preparations containing antihistamines or decongestants.
• Medications that prolong the QT interval, especially in patients with cardiac risk factors.